Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Preferred Stock Liabilities (2018 - 2019)

Revolution Medicines has reported Preferred Stock Liabilities over the past 2 years, most recently at $305.1 million for Q4 2019.

  • Quarterly results put Preferred Stock Liabilities at $305.1 million for Q4 2019, up 48.77% from a year ago — trailing twelve months through Dec 2019 was $305.1 million (up 48.77% YoY), and the annual figure for FY2019 was $305.1 million, up 48.77%.
  • Preferred Stock Liabilities for Q4 2019 was $305.1 million at Revolution Medicines, roughly flat from $305.1 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for RVMD hit a ceiling of $305.1 million in Q3 2019 and a floor of $205.1 million in Q4 2018.